Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
7 min read
Catalyst Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Catalyst Biosciences, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
CEL-SCI Corporation Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
CEL-SCI Corporation 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Cellerant Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Cellerant Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Cellectis S.A. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Cellectis S.A. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Caribou Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Caribou Biosciences, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
6 min read
CARLINA Technologies S.A.S. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
CARLINA Technologies S.A.S. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Captor Therapeutics spolka akcyjna Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Captor Therapeutics spolka akcyjna 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
6 min read
Cardiorentis AG Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Cardiorentis AG 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Cardior Pharmaceuticals GmbH Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Cardior Pharmaceuticals GmbH 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
CalciMedica, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
CalciMedica, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
6 min read
CANbridge Life Sciences Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
CANbridge Life Sciences Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Candel Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Candel Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
<
1
<<
384
385
386
387
388
>>
1536
>